Provided by Tiger Trade Technology Pte. Ltd.

Verrica Pharmaceuticals Inc.

4.82
-0.0400-0.82%
Pre-market: 5.550.7300+15.15%04:02 EDT
Volume:78.82K
Turnover:375.59K
Market Cap:82.80M
PE:-2.77
High:4.99
Open:4.90
Low:4.64
Close:4.86
52wk High:9.82
52wk Low:3.28
Shares:17.18M
Float Shares:6.78M
Volume Ratio:0.66
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7400
EPS(LYR):-1.6791
ROE:-240.35%
ROA:-43.98%
PB:19.22
PE(LYR):-2.87

Loading ...

Verrica Pharmaceuticals CEO buys $125.8K in common stock

TIPRANKS
·
Aug 19

Verrica Interim CFO John J. Kirby Acquires $24,650 of Common Shares

Reuters
·
Aug 19

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG)

TIPRANKS
·
Aug 08

Verrica Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Verrica Pharma Reports Wider-than-Expected Q2 Adj Loss Per Share

Reuters
·
Aug 07

Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate

Benzinga Earnings
·
Aug 07

Verrica Pharmaceuticals Q2 Income from Operations USD -13.097 Million

THOMSON REUTERS
·
Aug 07

Verrica Pharmaceuticals Q2 Adjusted EPS USD -0.48

THOMSON REUTERS
·
Aug 07

Verrica Pharmaceuticals Closes Credit Facility for up to $27.5 Million with Entity Controlled by Chairman Paul Manning

Reuters
·
Aug 07

Verrica Pharmaceuticals Closes Credit Facility for up to $27.5 Million in Non-Dilutive Growth Capital

THOMSON REUTERS
·
Aug 07

Verrica Pharmaceuticals Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Verrica Pharmaceuticals Schedules Conference Call to Discuss Q2 Results, Corporate Update

Reuters
·
Jul 30

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

THOMSON REUTERS
·
Jul 30

Verrica Signs Exclusive Deal with Medomie to Market Ycanth in Israel

Reuters
·
Jul 21

Verrica Pharmaceuticals: Granted Medomie Exclusive Right to Obtain & Maintain Marketing Authorizations for Ycanth in Israel

THOMSON REUTERS
·
Jul 21

Verrica Pharmaceuticals Inc: Eligible to Receive up to $8.2 Mln in Total Regulatory and Commercial Milestones

THOMSON REUTERS
·
Jul 21

Verrica Pharmaceuticals Inc: Will Receive 60% of Net Selling Price of Product Sold by Medomie in Israel

THOMSON REUTERS
·
Jul 21

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize Ycanth® for the Treatment of Molluscum Contagiosum in Israel

THOMSON REUTERS
·
Jul 21

Verrica Pharmaceuticals' Doses First US Patient in Phase 3 Trial Evaluating Ycanth to Treat Common Warts

MT Newswires Live
·
Jun 22

Verrica doses first US patient in pivotal Phase 3 COVE-3 trial of YCANTH for common warts

Reuters
·
Jun 22